Gossamer Bio vs Protagonist Therapeutics
Gossamer Bio reported revenue of $48 million in fiscal 2025, about the same as Protagonist Therapeutics' $46 million in fiscal 2025. Gossamer Bio's revenue fell 57.7% in its latest year, and Protagonist Therapeutics' fell 89.4%. Gossamer Bio had an operating margin of -352.2%, against -343.6% at Protagonist Therapeutics. Free cash flow was −$171 million at Gossamer Bio and $56 million at Protagonist Therapeutics.
Side by side
| Gossamer Bio | Protagonist Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $48M | $46M |
| Revenue growth | −57.7% | −89.4% |
| Revenue growth a year, last 5 years | — | 10.0% |
| Gross margin | — | — |
| Operating margin | −352.2% | −343.6% |
| Net margin | −351.5% | −282.8% |
| Free cash flow | −$171M | $56M |
| Free cash flow margin | −353.5% | 121.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.0% | −2.3% |
| Last close | $11.23 | $124.02 |
| P/E at the last close | — | 26.3× |
| Insider trades, last 12 months | — | sold $79.5 million |
| Piotroski F-score | 0 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Gossamer BioProtagonist Therapeutics
Operating margin
Percent of revenue
Gossamer BioProtagonist Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gossamer BioProtagonist Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gossamer Bio and Protagonist Therapeutics pages.